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ASIC3Solid and hematologic cancer colonized bone produces a number of pathologies. One of the most common
complications is bone pain. Cancer-associated bone pain (CABP) is a major cause of increased morbidity and
diminishes the quality of life and affects survival. Current treatments do not satisfactorily control CABP and
can elicit adverse effects. Thus, new therapeutic interventions are needed to manage CABP. However, the
mechanisms responsible for CABP are poorly understood. The observation that speciﬁc osteoclast inhibitors
can reduce CABP in patients indicates a critical role of osteoclasts in the pathophysiology of CABP. Osteoclasts
create an acidic extracellular microenvironment by secretion of protons via vacuolar proton pumps during
bone resorption. In addition, bone-colonized cancer cells also release protons and lactate via plasma membrane
pH regulators to avoid intracellular acidiﬁcation resulting from increased aerobic glycolysis known as the
Warburg effect. Since acidosis is algogenic for sensory neurons and bone is densely innervated by sensory
neurons that express acid-sensing nociceptors, the acidic bonemicroenvironments can evoke CABP. Understand-
ing of the mechanism by which the acidic extracellular microenvironment is created in cancer-colonized bone
and the expression and function of the acid-sensing nociceptors are regulated should facilitate the development
of novel approaches for management of CABP. Here, the contribution of the acidic microenvironment created in
cancer-colonized bone to elicitation of CABP and potential therapeutic implications of blocking the development
and recognition of acidic microenvironment will be described. This article is part of a Special Issue entitled:
Membrane channels and transporters in cancers.
© 2015 Elsevier B.V. All rights reserved.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2678
2. Acidic extracellular microenvironment in cancer-colonized bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2678
2.1. Osteoclastogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2678
2.2. Role of osteoclasts in cancer colonization in bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2678
2.3. Bone resorption and proton release by mature osteoclasts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2678
2.4. Proton and lactate release by cancer cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2679
3. Acid-sensing machinery in bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2680
3.1. Innervation of nociceptive sensory neurons in bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2680
3.2. Acid-sensing receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2681
3.2.1. Transient receptor potential channel-vanilloid subfamily member 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2681
3.2.2. Acid-sensing ion channel 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2681
3.3. Other acid-sensing machineries potentially contributing to CABP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2681
4. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2682
Transparency document . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2683
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2683ne channels and transporters in cancers.
ematology/Oncology, Indiana University School of Medicine, Walther Hall R3-C321D, 980 W. Walnut Street, Indianapolis, IN
6.
sa@iu.edu (M. Hiasa), nagatay@iu.edu (Y. Nagata), tokui@iupui.edu (T. Okui), fawhite@iu.edu (F. White).
2678 T. Yoneda et al. / Biochimica et Biophysica Acta 1848 (2015) 2677–26841. Introduction
Common solid cancers such as breast cancer, prostate cancer and
lung cancer preferentially spread to bone [1]. Rare primary bonemalig-
nancies such as osteosarcoma, Ewing's sarcoma, and chondrosarcoma
also aggressively expand in bone [2]. Multiple myeloma, which is a
malignant plasma cell disorder accounting for approximately 10% of
all hematologic cancers, exclusively colonizes bone [3]. These bone-
colonizing cancers induce the development of either osteolytic,
osteosclerotic or mixed bone disease by disrupting the homeostasis of
bone environment. In addition, they are associated with skeletal-
related events including bone pain, pathologic fractures, hypercalcemia,
spinal cord compressions, palliative radiotherapy to bone and surgery to
bone to treat or prevent a fracture during the clinical course of the
disease [4]. Of these, bone pain is one of the most common and detri-
mental complications associated with cancer colonization in bone [5].
Cancer-associated bone pain (CABP) profoundly diminishes quality of
life, impairs host immune surveillance and delays recovery from the
illness, leading to increased secondary death. Accordingly, control of
bone pain is a major goal for medical oncologists to achieve in theman-
agement of cancer patients. However, current treatments for CABP are
not satisfactory and adequate and have serious side effects. Thus, new
effective therapeutic interventions for CABP with reduced adverse
effects need to be developed. Despite these circumstances, little is
known about the mechanism of CABP.
Although the mechanism of CABP is poorly understood, accumulat-
ing clinical studies have shown that the speciﬁc inhibitors of osteoclasts,
bisphosphonate and denosumab, signiﬁcantly reduce CABP [6,7].
Osteoclasts are the principal bone resorbing cells in physiological and
pathological conditions associated with increased bone resorption [8].
They play a central role in the pathophysiology of cancer colonization
in bone [1]. These results collectively suggest that factors released at
the tumor–bone interface during osteoclastic bone resorption may be
an important mechanism of CABP. However, it should be noted that
suppression of osteoclastic bone resorption fails to prevent the progres-
sion of CABP as the disease advances [7], conﬁrming that not only
osteoclasts but also cancer cells contribute to the pathophysiology of
CABP.
In cancer-colonized bone microenvironment, osteoclasts, cancer
cells, and cancer-associated stromal cells and inﬂammatory immune
cells produce varieties of algogenic mediators that can excite and sensi-
tize peripheral nociceptive sensory neurons and evoke pain through
binding to their cognitive receptors present on the sensory neurons
[9–11]. Protons are one of these algogenic mediators [9–11]. Of note,
osteoclasts release protons via the plasma membrane (a3 isoform)
vacuolar-H+-ATPase coupled with chloride channels to secrete hydro-
chloric acid to degrade bone minerals during bone resorption [8,12].
In addition, it has been well-recognized that aggressive cancer cells
secrete substantial levels of protons/lactate into the extracellular envi-
ronments to avoid intracellular acidiﬁcation due to elevated aerobic
glycolysis known as the Warburg effect [13]. Thus, protons released
from osteoclasts and cancer cells co-operatively create an acidic
extracellular microenvironment in cancer-colonized bone.
Here we will overview the role of the acidic microenvironment
created by protons/lactate released from bone-resorbing osteoclasts
and bone-colonizing cancer cells in the pathophysiology of CABP with
our recent experimental observations.
2. Acidic extracellular microenvironment in cancer-colonized bone
2.1. Osteoclastogenesis
Osteoclasts are multinucleated giant cells formed by the fusion of
mononuclear progenitors of the monocyte/macrophage lineage [8].
They are the principal bone resorbing cells and play a central role
in the formation of the skeleton and regulation of its mass. Forosteoclast formation from the osteoclast precursors, macrophage
colony-stimulating factor (M-CSF) and receptor for activation of nuclear
factor kappa B (NF-κB) (RANK) ligand (RANKL) [14] produced in
neighboring osteoblasts or stromal cells are essential [8] (Fig. 1).
RANKL is a member of the tumor necrosis factor family and primarily
a membrane-bound cytokine. Therefore, osteoclast precursors that ex-
press receptors for RANKL, RANK, need to contact with osteoblasts or
stromal cells to differentiate into mature osteoclasts. Osteoprotegerin
(OPG) is a natural soluble decoy receptor that competes with RANK
for RANKL and thus inhibits RANKL-induced osteoclast formation and
bone resorption [8]. The balance between the expression of RANKL
and OPG (RANKL/OPG ratio) controls osteoclastogenesis and the degree
of resulting bone resorption. Mice lacking M-CSF, RANKL or RANK
showedosteopetrosis due to decreased osteoclastogenesis and dysfunc-
tion ofmature osteoclasts [14]. On the other hand,mice deﬁcient of OPG
exhibited severe osteopenia due to increased osteoclastogenesis and
bone resorption [14]. The mutations in the signal peptide region of the
RANK protein cause familial expansile osteolysis, a rare autosomal
dominant disorder characterized by focal areas of enhanced bone
resorption, and familial Paget's disease [15]. OPG deﬁciency due to
homozygous loss-of-function mutations within the TNFRSF11B gene is
a cause of juvenile Paget's disease [16]. Thus, osteoclasts are evidently
the principal causative player in diverse bone disorders.
2.2. Role of osteoclasts in cancer colonization in bone
In cancer-colonized bone and bone metastasis, osteoclasts are
increased and activated to destroy bone by factors produced by cancers
[1,17,18]. Bone destruction, in turn, further stimulates the colonization
of cancer cells in bone via the release of bone-stored growth factors in-
cluding transforming growth factor-β (TGF-β) and insulin-like growth
factors (IGFs). This interactive process between bone-colonizing cancer
cells and bone-resorbing osteoclasts is called “the vicious cycle” (Fig. 2).
Thus, osteoclasts are a central regulatory player in the pathophysiology
of cancer colonization in bone and bonemetastasis. However, their role
in CABP remains poorly understood.
2.3. Bone resorption and proton release by mature osteoclasts
Signiﬁcant reduction of bone pain by the speciﬁc inhibitors of osteo-
clastic bone resorption, bisphosphonates and denosumab, in patients
with multiple myeloma and solid cancers [6,7,19,20] indicates a critical
role of osteoclasts in the pathophysiology of CABP. Consistent with
these clinical observations, Honore et al. [21] reported that OPG,
which inhibits osteoclast formation and bone resorption through
interfering RANKL binding to RANK [8], suppressed CABP using an
experimental animal model. We also showed that the most potent
bisphosphonate zoledronic acid signiﬁcantly reduced CABP [22]. It is
therefore important to understand how osteoclasts resorb bone to
gain better insights into the mechanism underlying CABP.
Bone resorption by mature osteoclasts is a dynamic multi-step
process [8]. First, osteoclasts migrate and attach tightly to the bone sur-
face targeted for degradation and removal via theαvβ3 integrin, thereby
forming a tight “sealing zone”. Plasmamembrane then polarizes to form
the resorption organelle, called “rufﬂed border”. The rufﬂed border is a
unique folded highly permeable membrane facing the resorbing bone
surface. To dissolve bone minerals, protons (H+) and chloride ions
(Cl−) is released via the plasma membrane (a3 isoform) vacuolar H+-
ATPase proton pump [23] and chloride ion-proton anti-porter ClC-7
[24] clustered in the rufﬂed border into the resorption lacunae, acidify-
ing the resorptive lacunae to a pH of ∼4.5 [8]. Concomitantly, the
cysteine peptidase cathepsin K [25] degrades bone matrix. The degrad-
ed bonematrix is trans-endocytosed from the resorption lacunae to the
“functional secretory domain” and released into the extracellular
environment [26]. Finally, osteoclasts gone through bone resorption
detach from the bone surface and undergo apoptosis [8].
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Fig. 1. Proton secretion by bone-resorbing osteoclasts. To dissolve bone minerals, mature osteoclasts release protons (H+) and chloride ions (Cl−) into the resorption lacunae via the
plasmamembrane (a3 isoform) vacuolar H+-ATPase proton pump [23] and chloride ion-proton anti-porter ClC-7 [24], acidifying the resorption lacunae to a pHof ∼4.5 [7]. Concomitantly,
the lysosomal cysteine peptidase cathepsin K [25] degrades bone matrix including type I collagen. RANKL stimulates osteoclastogenesis and bone resorption and prolongs survival by
inhibiting apoptosis. CAII: carbonic anhydrase II, ClC7: plasmamembrane chloride ion-proton anti-porter, RANK: receptor activation of NF-κB, RANKL: receptor activation of NF-κB ligand,
V-H+-ATPase: plasma membrane (a3 isoform) vacuolar H+−ATPase proton pump.
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resorbing osteoclasts strongly express a3 vacuolar-H+-ATPase on their
plasma membrane, while another acid-secreting tissue, the gastric
epithelium exhibited marginal expression of a3 vacuolar-H+-ATPase
(unpublished data). On the other hand, the gastric epitheliumdisplayed
high expression of p-type-H+-ATPase [27], while the expression of p-
type-H+-ATPase in osteoclasts was undetectable. These data suggest
that algogenic protons released from bone-resorbing osteoclasts via a3
vacuolar-H+-ATPase into the extracellular microenvironment likely
impact pH-sensitive peripheral nerve ﬁbers and directly contribute to
bone pain. In support of this notion, we reported that the non-
selective vacuolar-H+-ATPase inhibitor, baﬁlomycin A1 reduces inﬂam-
matory bone pain [28]. Moreover, we recently found that baﬁlomycin
A1 blocked the development of acidic environment in cancer-
colonized bone determined by acridine orange staining [29] and
signiﬁcantly reduced CABP (unpublished data). Of interest, the p-type-
H+-ATPase inhibitor, rabeprazole [30] that is widely used for the treat-
ment of gastric pain failed to suppress CABP. The pathophysiology of
CABP may be thus unique compared with that of other types of pain
because of the contribution of osteoclast a3 vacuolar-H+-ATPase.
Many classes of inhibitors of osteoclast proton pump for the treatment
of osteoporosis are currently developed and tested in pre-clinical and
clinical settings. It is expected that these agents not only inhibit bone
resorption but also alleviate CABP.
2.4. Proton and lactate release by cancer cells
The failure of inhibitors of osteoclastic bone resorption to block the
progression of CABP in patients [7,20] and tumor-bearing animals [21,
22] indicates that osteoclasts are not the only cells contributing to
CABP. Undoubtedly, cancer cells, inﬂammatory cells and immune cells
contribute to the pathophysiology of CABP as well. Cancer cells produce
varieties of nociceptive substances including protons, proteases, gluta-
mate, lysophosphatidic acid, prostaglandins, nerve growth factors,endothelin, bradykinin, extracellular adenosine triphosphate and pro-
inﬂammatory cytokines and chemokines such as interleukins, tumor
necrosis factors and macrophage inﬂammatory protein-1 [9–11].
Among these, the contribution of protons released from cancer cells,
in addition to osteoclasts, to the pathophysiology of CABP will be
discussed here.
Some regions of cancer environment are hypoxic due to inadequate
oxygen delivery, which limits oxidative phosphorylation that efﬁciently
produces ATP via glucose metabolism in the mitochondria in normal
cells [13]. To meet increased requirements for ATP and metabolic inter-
mediates and precursors to maintain their aggressiveness, hypoxic
cancer cells shift their energy metabolism to glycolysis that is much
less energy-efﬁcient but independent of oxygen. The elevated aerobic
glycolysis, known as the Warburg effect, consumes high glucose and
produce substantial amounts of lactate that lowers intracellular pH
[13]. To avoid intracellular acidiﬁcation, cancers actively extrude lactate
and protons via plasma membrane pH regulators such as monocarbox-
ylate transporter 1 and 4 (MCT1 andMCT4), Na+/H+ exchangers, anion
exchangers, carbonic anhydrases, V-H+-ATPase, Na+/HCO3− co-
transporters andHCO3− transporter, creating acidic extracellular cancer
microenvironment [31]. We showed that high-metastatic B16 mouse
melanoma cells expressed increased levels of the a3 isoform V-H+-
ATPase compared to the low-metastatic B16 parental cells. Knockdown
of a3 V-H+-ATPase suppressed invasiveness and migration and signiﬁ-
cantly decreased lung and bone metastases [32], suggesting that a3 V-
H+-ATPase promotes distant metastasis of B16 melanoma cells by
creating acidic environments via proton secretion. From these results,
we propose that inhibition of the development of cancer-associated
acidic environments by suppressing a3 V-H+-ATPase could be a novel
therapeutic approach for the treatment of cancermetastasis. The poten-
tial of the inhibitors of aerobic glycolysis (Warburg effect) [33] and
these proton pumps [31] as anti-cancer drugs has been extensively
explored. However, the effects of these inhibitors on CABP are
unknown. Determination of the effects of these inhibitors on CABP
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Fig. 2. Vicious cycle between osteoclasts and cancer cells in bone. Bone-derived growth factors (GFs) such as insulin-like growth factors (IGF) and transforming growth factor-β (TGF-β),
promote proliferation and inhibit apoptosis and stimulate epithelial–mesenchymal transition (EMT) and production of bone-modifying cytokines such as parathyroid hormone-related
protein (PTH-rP), prostaglandin E2 (PGE2) and interleukin-11 (IL-11) in bone-colonizing cancer cells, representing the concept of “Seed and Soil” theory proposed by Paget [81]. These
bone-modifying factors further stimulate osteoclastic bone resorption via activation of receptor activator of nuclear factor-κB (RANKL)/RANK pathway in osteoblasts and osteoclasts,
thereby further increasing release of bone-stored growth factors, thus establishing “vicious cycle” between bone-resorbing osteoclasts and bone-colonizing cancer cells [1,17,18]. Bone-
colonizing cancer cells reside in stromal cell niche via cell–cell contact that is mediated by cell adhesion molecules (CAMs) and stay dormant or undergo EMT and acquire further
aggressiveness. Role of osteocytes in bonemetastasis and CABP needs to be elucidated. CAM: cell adhesion molecule, EMT: epithelial–mesenchymal transition, RANK: receptor activation
of NF-κB, RANKL: receptor activation of NF-κB ligand.
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MCT1 and MCT4 are two of the major proton-coupled lactate
symporters mediating bidirectional lactate transport across the plasma
membrane [34]. Many cancer cells express MCT1 and MCT4 through
which substantial amounts of lactate resulting from theWarburg effect
are released [35]. Of note, MCT expression in cancer is correlated with
outcome of breast cancer patients [36]. Thus extracellular lactate levels
are likely elevated in cancer environment. Recent studies reported that
lactate released viaMCTs from astrocytes is not a waste of glycolysis but
rather an energy source shuttling between astrocytes and neurons [37,
38], suggesting that lactate is a critical regulator of neuronal function.
Therefore, nociceptive sensory neurons can also be activated by lactate
released via MCTs from aggressive cancer cells to evoke CABP.
We have recently found that MCT1 and MCT4 are expressed in
multiplemyeloma cells isolated frompatients and several lines of breast
cancer cells and multiple myeloma cells (unpublished data). These
cancer cells secreted lactate via MCTs and lower extracellular pH.
Furthermore, dorsal root ganglion (DRG) sensory neurons also
expressedMCT1 andMCT4. Acidic environment (pH 6.5) created by lac-
tate stimulated an excitation of DRG sensory neuronal cells determined
by intracellular Ca2+ mobilization using Fura-2 calcium imaging assay.
More importantly, we found that the non-speciﬁc MCT antagonist, α-
cyano-4-hydroxycinnamate (CHC) [39] reduced CABP in an animal
model. MCT inhibitors such as CHC are also shown to have anti-cancer
effects and some of them are in Phase I clinical trials for advanced
solid tumors and for diffuse large B-cell lymphoma [35]. Our results to-
gether with these earlier results suggest that MCT inhibitors could be
developed as drugs that inhibit tumor growth and CABP.3. Acid-sensing machinery in bone
3.1. Innervation of nociceptive sensory neurons in bone
It has been proposed that the densely innervated periosteum is the
primary site from which bone pain arises. However, patients often
complain of bone pain even if cancer localizes to bone marrow or min-
eralized bone and in the absence of evident periosteal involvement [40],
indicating the presence of sensory nerve ﬁbers in non-periosteal sites in
bone. An early study using transmission electron microscopy described
by Cooper demonstrated that nerve ﬁbers are present in cortical bone
[41]. Furthermore, data are accumulating that bone is densely innervat-
ed [40,42–44]. Of note, Mach et al. reported that the bone marrow had
the greatest total number of sensory ﬁbers, followed by mineralized
bone and then periosteum [40]. Consistent with these earlier studies,
we also showed that calcitonin gene-related peptide (CGRP)-positive
sensory neurons innervate the mineralized bone and bone marrow.
CGRP has been widely used as a marker for sensory neurons and impli-
cated inmigraine [45]. Mice lacking CGRP showed attenuated responses
to nociceptive chemicals and inﬂammation [46].
The sensory neurons innervating bone are distal nerve ﬁbers from a
number of subpopulations of primary afferent sensory neurons associ-
atedwith lumbarDRG (L3-L5) [40,47]. These cell populations are largely
subdivided by the presence of neuroﬁlament (NF) 200-positive (A-δ)
and CGRP-positive (A-δ or peptidergic C ﬁbers). Bone can be further
distinguished by the general lack of innervation by the non-
peptidergic subpopulation of neurons that bind isolectin B4 (IB4) [47].
Though functional distinction of these neurons is not fully understood,
CGRP-positive peptidergic C-ﬁbers detect noxious stimuli and are
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positive sensory neurons exhibited pathological sprouting in the
presence of bone cancer [49]. Nerve growth factor (NGF) derived from
cancer cells and stromal cells is likely responsible for the sprouting of
sensory neurons, since anti-NGF neutralizing antibody blocked the
sprouting and reduced CABP [49]. This pathological remodeling of the
peripheral sensory ﬁbers may exacerbate CABP, making control of
CABP difﬁcult. We observed similar sprouting of CGRP-positive sensory
neurons in bone colonized by breast cancer cells andmultiple myeloma
cells (unpublished data). These results suggest that the products in
cancer-colonized bone environment promote the sensory neurons
innervating bone to remodel and enhance CABP.
3.2. Acid-sensing receptor
Based on previous and our results, it is likely that the pathological
acidic microenvironments created by protons/lactate secreted
from bone-resorbing osteoclasts and bone-colonizing cancer cells up-
regulate and activate acid-sensing nociceptors expressed on sensory
neurons to evoke CABP. Two of the speciﬁc and representative pH-
sensitive acid-sensing nociceptors that are related to acid-induced
bone pain are the transient receptor potential channel-vanilloid
subfamily member 1 (TRPV1) and the acid-sensing ion channel 3
(ASIC3) [48].
3.2.1. Transient receptor potential channel-vanilloid subfamily member 1
The TRPV1/vanilloid receptor 1 (VR1)/capsaicin receptor, whichwas
cloned from vertebrates by Caterina et al. [50], is a family member of
transient receptor potential (TRP) ion channels expressed on a subset
of nociceptive sensory neurons. It is activated by heat (N42 °C) and
acid (bpH 6.0) and is the only channel that is excited by the vanilloid
capsaicin [50,51]. In bone TRPV1 is found to express in osteoblasts and
osteoclasts and regulate their differentiation and function [52].
Using a mouse model of inﬂammatory pain [53], we showed that
TRPV1 was co-expressed on CGRP-positive sensory neurons in DRG.
Mice with inﬂammation in their hind-paw exhibited a nociceptive
behavior (thermal hyperalgesia) with elevated CGRPmRNA expression
in the DRG. Treatment by acid (pH 5.5) excited primary DRG sensory
neuron cells and increased CGRP mRNA expression and protein
production in these cells. The speciﬁc antagonist of TRPV1, 5′-
iodoresiniferatoxin (I-RTX), blocked the excitation and the acid-
increased CGRP expression and production. Further, primary DRG cells
isolated from TRPV1−/− mice failed to show an increase in CGRP
expression upon treatment with acid. Of importance, inﬂammatory
pain was markedly diminished in TRPV1 −/− mice. These results
collectively suggest that activation of TRPV1 in inﬂammatory acidic
environment leads to an up-regulation of CGRP expression, which in
turn further increases inﬂammation and pain. Thus, blockade of
TRPV1, CGRP or both could be an effective pharmacological intervention
for acid-associated inﬂammatory pain.
TRPV1 has been implicated in the pathophysiology of CABP [9,11,
54]. In preclinical models of cancer pain, TRPV1 expression was
increased in the ipsi-lateral DRG in the presence of cancer in bone [55,
56]. In support of the important role of TRPV1 in CABP, TRPV1 gene
disruption or TRPV1 antagonist reduces CABP [57]. Similarly, the specif-
ic TRPV1 antagonist I-RTX also suppressed CABP [56]. Of interest, the
TRPV1 antagonist SB366791 was shown to potentiate analgesic effects
of morphine on bone cancer pain [58]. These data suggest that suppres-
sion of TRPV1 activation under the acidic cancer environment is a
promising therapeutic approach to attenuate CABP. However, preclini-
cal and clinical studies revealed that TRPV1 antagonists induce
hyperthermia as an adverse effect [59]. Attempts to develop or identify
antagonists devoid of temperature effects have not been successful. In
this context, it is noted that recent studies have shown that the expres-
sion and activity of TRPV1 on theDRG sensory neurons are up-regulated
by transforming growth factor-β1 (TGF-β1) [60] and insulin-likegrowth factor-1 (IGF-1) [61]. Since TGF-β and IGF-1 are abundantly
stored in bone and released as a consequence of bone resorption by
cancer-activated osteoclasts, expression and activation of TRPV1 on
the sensory neurons innervating bone may be modulated by these
bone-derived growth factors. In fact, these studies showed that inhibi-
tion of TGF-β [60] or IGF receptor signaling [61] reduced CABP due to
suppression of TRPV1 activation. Suppression of TRPV1 activity and
expression by blocking the activity of growth factors released from
bone may be an alternative approach to attenuate CABP.
3.2.2. Acid-sensing ion channel 3
ASIC3 is a pH sensor predominantly expressed in primary afferent
sensory neurons [62,63]. In DRG, ASIC3 expression was increased in
inﬂammatory acidic conditions and co-expressedwith CGRP in the sen-
sory neurons innervating the knee joint, indicating ASIC3 contribution
to acute arthritis pain [64]. ASIC3 was also detected on the CGRP-
positive sensory neurons innervating periosteal surface of bone [65].
In bone ASIC3 is present in monocytes, osteoclasts and osteoblasts
[66]. However, its functional role in bone homeostasis is unclear.
A recent study that showed that an injection of the synthetic ASIC3
agonist, 2-guanidine-4-methylquinazoline into mouse paw induced
noxious behaviors in wild-type mice but not ASIC3−/− mice [67]
provided that the evidence that ASIC3 activation is sufﬁcient to evoke
pain [68]. However, the role of ASIC3 in CABP still remains elusive. We
reported that ASCI3 mRNA expression was up-regulated in DRG associ-
atedwith CABP in amodel of ratmammary tumor [55]. In support of our
results, Qiu et al. [69] recently showed ASIC3 expressionwas elevated in
DRG using a different model of rat mammary tumor. Although these
results suggest that ASIC3 is involved in the pathophysiology of CABP,
it needs to be shown that suppression of increased ASIC3 expression
in DRG leads to reduced CABP and that CABP is alleviated in ASIC3
knockout mice. We have recently found that, upon acid treatment
(pH 6.5), primary sensory neuron cells isolated from DRG displayed
Ca2+ inﬂux (unpublished data), which is a widely-used early indicator
for sensory neuron excitation [70]. Of note, the speciﬁc ASIC3 antagonist
APETx2 [71] inhibited Ca2+ inﬂux, indicating a critical role of ASIC3 in
sensory neuron excitation. Of interest, APETx2 was shown to reduce
acid-induced and inﬂammatory pain due to complete Freund's adjuvant
in rat [72] and slowed the progression of the disease in a rat model of
osteoarthritis [73]. It is intriguing to examine the effects of APETx2 on
CABP.
ASIC3 sensesmild extracellular acidiﬁcation (pH 6.8–7.0) [63], while
TRPV1 is activated at a pH lower than 6.0 [50,51]. We reported that
TRPV1 was activated at pH 5.5 [53]. The pH of the acidic environment
created by cancer cells is shown to be 6.5–7.0 [31] and that by bone-
resorbing osteoclasts is assumed to be 4.0–4.5 [23]. Sensory neurons
innervating bone may be excited and sensitized by discriminating
mild and strong acidic extracellular microenvironment through ASIC3
and TRPV1 in the pathophysiology of CABP, respectively (Fig. 3).
3.3. Other acid-sensing machineries potentially contributing to CABP
Transient receptor potential (TRP) ion channels are the large
families of cellular sensors mediating taste perception, thermo-
sensation, mechano-sensing and osmolality sensing by transducing
various physical stimuli into neuronal signals in predominantly C and
Aδ nociceptors in primary sensory neurons [74]. Further, TRP ion chan-
nels also mediate transduction of peripheral nociceptive stimuli into
pain. Of interest, recent studies described that the members of TRP
channels are involved in the regulation of skeletal homeostasis through
affecting intestinal calciumabsorption (TRPV6), renal calcium reabsorp-
tion (TRPV5), and differentiation of osteoclasts (TRPV1, TRPV2, TRPV4,
TRPV5), chondrocytes (TRPV4) and osteoblasts (TRPV1) [52]. It is thus
tempting to propose that these family members of TRP channels play
a role in acid-induced CABP. However, current available evidence
suggests that acid unlikely activates these TRPVs except for TRPV1.
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Fig. 3. Acid-evoked cancer-associated bone pain (CABP). Bone-resorbing osteoclasts secrete protons via plasma membrane a3 V-H+-ATPase to degrade bone minerals. Bone-colonizing
cancer cells also release protons/lactate via MCT, a3 V-H+-ATPase and other proton pumps including Na+/H+ exchangers, anion exchangers, carbonic anhydrases, Na+/HCO3- co-trans-
porters and HCO3- transporter to avoid intracellular acidiﬁcation due to the Warburg effect. The pH of the acidic environment created by cancer cells and bone-resorbing osteoclasts is
assumed to be 6.5–7.0 [31] and 4.0–4.5 [23], respectively. The acidicmicroenvironment directly excites and sensitizes sensory neurons innervating bone via activation of the acid-sensing
nociceptors, TRPV1 and ASIC3, transducing noxious signals to via DRG (primary afferent neuron) and spinal cord (secondary afferent neuron) and evoke bone pain in brain. TRPV1
activation promotes eCa2+ inﬂux into cytoplasm and induces propagation of intracellular signaling molecules including calmodulin kinase II (CaMKII) and the transcription factor
cAMP responsive element-binding protein (CREB), leading to transcriptional activation of target molecules [52]. TRPV1 activation also propagates Erk and Akt presumably to prevent
apoptosis of neuron cells. Blockade of TRPV1 activation under the acidic cancer environmentsmay be a promising therapeutic approach to alleviate CABP. ASIC3: acid-sensing ion channel
3, CAMKII: calmodulin kinase II, CGRP: calcitonin gene-related peptide, CREB: cAMP responsive element-binding protein, DRG: dorsal root ganglion, MCT: monocarboxylate transporter,
TRPV1: transient receptor potential channel-vanilloid subfamily member 1.
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channel that uniquely possesses 17 ankyrin repeat domains [74].
TRPA1 is predominantly expressed C and Aδ nerve ﬁbers. Although
still controversial, TRPA1 is proposed to be activated by noxious cold
temperatures (b18 °C) andmechanical force and some studies reported
that TRPA1 deﬁcient mice showed impaired behavioral responses to
cold plate and mechanical stimuli. Expression of TRPA1 in bone cells
has been unknown but a recent study demonstrated the expression of
TRPA1 in human odontoblasts [75]. It is unclear whether TRPA1 is
activated by acid and plays a role in CABP. Notably, however, most neu-
rons that express TRPA1 also express TRPV1, raising the possibility that
TRPA1 may modulate or partially share the acid-sensing functions of
TRPV1. In case this is proved to be the case, hyperthermia, which is a
major obstacle in the development of TRPV1 antagonists, may not be a
serious problem with TRPA1 antagonists.
TRPMelastatin 8 (TRPM8) is expressed in a subset of C and Aδ nerve
ﬁbers in DRG, trigeminal ganglion and nodose ganglion [74]. In bone,
TRPM8 expression was shown in osteoblasts, however, its functional
role is unknown [76]. TRPM8 is activated by cold temperatures
(b15 °C) and ‘cooling’ compounds such as menthol and icilin and
peppermint oil. In contrast, it is unclear whether TRPM8 is activated
by acid. TRPM8 was initially cloned as a molecule that has high homol-
ogy to a TRP-like channel that was identiﬁed in prostate cancers [74].
Later, it was found that increased expression of TRPM8 is correlated
with the aggressiveness of a variety of cancers including prostate,
lung, breast, gastric, ovarian and liver cancer and melanoma [77].
Since prostate, breast and lung cancers preferentially spread to bone
and are frequently associated with CABP, it is plausible to speculate
that TRPM8 contributes to the pathophysiology of CABP. The role of
TRPM in CABP needs to be elucidated.4. Conclusion
Bone is a unique organ in which multinucleated giant osteoclasts
continuously secrete protons to maintain bone homeostasis in physio-
logical conditions [8]. The secretion of protons by osteoclasts is
increased in response to the bone-modifying factors produced by
bone-colonizing cancer cells [1,17,18]. Protons and lactate are also
secreted by bone-colonizing cancer cells as a consequence of elevated
oxygen-independent glycolysis (Warburg effect) [13,31]. In addition
to autonomous secretion of protons, osteoclasts and cancer cells may
further increase proton and lactate secretion in bonemicroenvironment
that is relatively hypoxic [78]. Hypoxia is shown to up-regulate the
expression and function of the plasma membrane proton/lactate
transporters [31]. Therefore, it is likely that cancer-colonized bone
microenvironment readily falls into pathological acidosis and that the
contribution of acid is more speciﬁc and critical in the pathophysiology
of CABP than that of other types of pain. In addition, accumulating
evidence indicates that the acidic extracellular microenvironments
critically inﬂuence malignant behaviors of cancer including invasive-
ness, metastasis, and chemo- and radio-resistance and thus are
associated with poor prognosis [79,80]. Accordingly, suppression of
the creation of acidic extracellular cancer-colonized bone microenvi-
ronment through inhibition of the function of the proton/lactate
transporters in osteoclasts and cancer cells seems likely to simulta-
neously inhibit cancer aggressiveness and CABP. Furthermore,
pharmacological agents that interfere with the activation of acid-
sensing nociceptors in sensory neurons associated with bone will be
an effective and selective therapeutic means for CABP. Finally, develop-
ment of new analgesic drugs for CABP is expected to reduce dosing of
opioids that are currently the primary agent in the management of
2683T. Yoneda et al. / Biochimica et Biophysica Acta 1848 (2015) 2677–2684cancer pain but cause unwanted adverse effects. Control of CABPwill be
a challenging goal in the management of patients with cancers in bone.
Transparency document
The Transparency document associated with this article can be
found, in the online version.
References
[1] K.N. Weilbaecher, T.A. Guise, L.K. McCauley, Cancer to bone: a fatal attraction, Nat.
Rev. Cancer 11 (2011) 411–425. http://dx.doi.org/10.1038/nrc3055 (PMID:
21593787).
[2] M. van Driel, J.P. van Leeuwen, Cancer and bone: a complex complex, Arch. Biochem.
Biophys. (2014)http://dx.doi.org/10.1016/j.abb.2014.07.013 (PMID: 25046842).
[3] E. Terpos, J. Berenson, N. Raje, G.D. Roodman, Management of bone disease in
multiple myeloma, Expert. Rev. Hematol. 7 (2014) 113–125. http://dx.doi.org/10.
1586/17474086.2013.874943 (PMID: 24433088).
[4] J.E. Brown, R.J. Cook, A. Lipton, L. Costa, R.E. Coleman, Prognostic factors for skeletal
complications from metastatic bone disease in breast cancer, Breast Cancer Res.
Treat. (2010) 767–779. http://dx.doi.org/10.1007/s10549-010-0981-1 (PMID:
20574672).
[5] S. Mercadante, Malignant bone pain: pathophysiology and treatment, Pain 69
(1997) 1–19. http://dx.doi.org/10.1016/S0304-3959(96)03267-8 (PMID:
9060007).
[6] N. Kohno, K. Aogi, H. Minami, S. Nakamura, T. Asaga, Y. Iino, T. Watanabe, C. Goessl,
Y. Ohashi, S. Takashima, Zoledronic acid signiﬁcantly reduces skeletal complications
compared with placebo in Japanese women with bone metastases from breast
cancer: a randomized, placebo-controlled trial, J. Clin. Oncol. 23 (2005)
3314–3321. http://dx.doi.org/10.1200/JCO.2005.05.116 (PMID: 15738536).
[7] C.S. Cleeland, J.J. Body, A. Stopeck, R. von Moos, L. Fallowﬁeld, S.D. Mathias, D.L.
Patrick, M. Clemons, K. Tonkin, N. Masuda, A. Lipton, R. de Boer, S. Salvagni, C.T.
Oliveira, Y. Qian, Q. Jiang, R. Dansey, A. Braun, K. Chung, Pain outcomes in patients
with advanced breast cancer and bone metastases: results from a randomized,
double-blind study of denosumab and zoledronic acid, Cancer 119 (2013)
832–838. http://dx.doi.org/10.1002/cncr.27789 (PMID: 22951813).
[8] S.L. Teitelbaum, Bone resorption by osteoclasts, Science 289 (2000) 1504–1508.
http://dx.doi.org/10.1126/science.289.5484.1504 (PMID: 10968780).
[9] P.W. Mantyh, Cancer pain and its impact on diagnosis, survival and quality of life,
Nat. Rev. Neurosci. 7 (2006) 797–809. http://dx.doi.org/10.1038/nrn1914 (PMID:
16988655).
[10] B.L. Schmidt, D.T. Hamamoto, D.A. Simone, G.L. Wilcox, Mechanism of cancer pain,
Mol. Interv. 10 (2010) 164–178. http://dx.doi.org/10.1124/mi.10.3.7 (PMID:
20539035).
[11] A.N. Lozano-Ondoua, A.M. Symons-Liguori, T.W. Vanderah, Cancer-induced bone
pain: mechanisms and models, Neurosci. Lett. 557 (Pt. A) (2013) 52–59. http://dx.
doi.org/10.1016/j.neulet.2013.08.003 (PMID: 24076008).
[12] A. Qin, T.S. Cheng, N.J. Pavlos, Z. Lin, K.R. Dai, M.H. Zheng, V-ATPases in osteoclasts:
structure, function and potential inhibitors of bone resorption, Int. J. Biochem. Cell
Biol. 44 (2012) 1422–1435. http://dx.doi.org/10.1016/j.biocel.2012.05.014 (PMID:
22652318).
[13] S.K. Parks, J. Chiche, J. Pouysségur, Disrupting proton dynamics and energy
metabolism for cancer therapy, Nat. Rev. Cancer 13 (2013) 611–623. http://dx.doi.
org/10.1038/nrc3579 (PMID: 23969692).
[14] D.L. Lacey, W.J. Boyle, W.S. Simonet, P.J. Kostenuik, W.C. Dougall, J.K. Sullivan, J. San
Martin, R. Dansey, Bench to bedside: elucidation of the OPG-RANK-RANKL pathway
and the development of denosumab, Nat. Rev. Drug Discov. 11 (2012) 401–419.
http://dx.doi.org/10.1038/nrd3705 (PMID: 22543469).
[15] A.E. Hughes, S.H. Ralston, J. Marken, C. Bell, H. MacPherson, R.G.Wallace,W. van Hul,
M.P. Whyte, K. Nakatsuka, L. Hovy, D.M. Anderson, Mutations in TNFRSF11A,
affecting the signal peptide of RANK, cause familial expansile osteolysis, Nat.
Genet. 24 (2000) 45–48. http://dx.doi.org/10.1038/71667 (PMID: 10615125).
[16] F. Saki, Z. Karamizadeh, S. Nasirabadi, S. Mumm, W.H. McAlister, M.P. Whyte,
Juvenile Paget's disease in an Iranian kindred with vitamin D deﬁciency and novel
homozygous TNFRSF11B mutation, J. Bone Miner. Res. 28 (2013) 1501–1508.
http://dx.doi.org/10.1002/jbmr.1868 (PMID: 23322328).
[17] G.R. Mundy, Metastasis to bone: causes, consequences and therapeutic
opportunities, Nat. Rev. Cancer 2 (2002) 584–593. http://dx.doi.org/10.1038/
nrc867 (PMID: 12154351).
[18] T. Yoneda, S. Tanaka, K. Hata, Role of RANKL/RANK in primary and secondary breast
cancer, World J. Orthop. 4 (2013) 178–185. http://dx.doi.org/10.5312/wjo.v4.i4.178
(PMID: 24147253).
[19] E. Terpos, G. Morga, M.A. Dimopoulos, M.T. Drake, S. Lentzsch, N. Raje, O. Sezer, R.
García-Sanz, K. Shimizu, I. Turesson, T. Reiman, A. Jurczyszyn, G. Merlini, A.
Spencer, X. Leleu, M. Cavo, N. Munshi, S.V. Rajkumar, B.G. Durie, G.D. Roodman,
International Myeloma Working Group recommendations for the treatment of
multiple myeloma-related bone disease, J. Clin. Oncol. 31 (2013) 2347–2357.
http://dx.doi.org/10.1200/JCO.2012.47.7901 (PMID: 23690408).
[20] R. von Moos, J.J. Body, B. Egerdie, A. Stopeck, J.E. Brown, D. Damyanov, L.J.
Fallowﬁeld, G. Marx, C.S. Cleeland, D.L. Patrick, F.G. Palazzo, Y. Qian, A. Braun, K.
Chung, Pain and health-related quality of life in patients with advanced solid
tumours and bone metastases: integrated results from three randomized, double-
blind studies of denosumab and zoledronic acid, Support. Care Cancer (2013)3497–3507. http://dx.doi.org/10.1007/s00520-013-1932-2 (PMID: 23975226).
[21] P. Honore, N.M. Luger, M.A. Sabino, M.J. Schwei, S.D. Rogers, D.B. Mach, P.F. O'keefe,
M.L. Ramnaraine, D.R. Clohisy, P.W. Mantyh, Osteoprotegerin blocks bone cancer-
induced skeletal destruction, skeletal pain and pain-related neurochemical reorga-
nization of the spinal cord, Nat. Med. 6 (2000) (2000) 521–528. http://dx.doi.org/
10.1038/74999 (PMID: 10802707).
[22] M. Nagae, T. Hiraga, T. Yoneda, Acidic microenvironment created by osteoclasts
causes bone pain associated with tumor colonization, J. Bone Miner. Metab. 25
(2007) 99–104. http://dx.doi.org/10.1007/s00774-006-0734-8 (PMID: 17323179).
[23] N. Kartner, M.F. Manolson, Novel techniques in the development of osteoporosis
drug therapy: the osteoclast rufﬂed-border vacuolar H (+)-ATPase as an emerging
target, 2014. http://dx.doi.org/10.1517/17460441.2014.902155 (PMID: 24749538).
[24] C. Supanchart, L. Wartosch, C. Schlack, J. Kühnisch, D. Felsenberg, J.C. Fuhrmann, M.C.
de Vernejoul, T.J. Jentsch, U. Kornak, ClC-7 expression levels critically regulate bone
turnover, but not gastric acid secretion, Bone 58 (2014) 92–102. http://dx.doi.org/
10.1016/j.bone.2013.09.022 (PMID: 24103576).
[25] A.G. Costa, N.E. Cusano, B.C. Silva, S. Cremers, J.P. Bilezikian, Cathepsin K: its skel-
etal actions and role as a therapeutic target in osteoporosis, Nat. Rev. Rheumatol.
7 (2011) 447–456. http://dx.doi.org/10.1038/nrrheum.2011.77 (PMID:
21670768).
[26] H. Zhao, Membrane trafﬁcking in osteoblasts and osteoclasts: new avenues for
understanding and treating skeletal diseases, Trafﬁc 13 (2012) 1307–1314. http://
dx.doi.org/10.1111/j.1600-0854.2012.01395.x (PMID: 22759194).
[27] J.P. Morth, B.P. Pedersen, M.J. Buch-Pedersen, J.P. Andersen, B. Vilsen, M.G. Palmgren,
P. Nissen, A structural overview of the plasma membrane Na+, K+-ATPase and
H+-ATPase ion pumps, Nat. Rev. Mol. Cell Biol. 12 (2011) 60–70. http://dx.doi.
org/10.1038/nrm3031 (PMID: 21179061).
[28] M. Nagae, T. Hiraga, H.Wakabayashi, L. Wang, K. Iwata, T. Yoneda, Osteoclasts play a
part in pain due to the inﬂammation adjacent to bone, Bone 39 (2006) 1107–1115.
http://dx.doi.org/10.1016/j.bone.2006.04.033 (PMID: 16769263).
[29] K. Henriksen, M.G. Sørensen, V.K. Jensen, M.H. Dziegiel, O. Nosjean, M.A. Karsdal, Ion
transporters involved in acidiﬁcation of the resorption lacuna in osteoclasts, Calcif.
Tissue Int. 83 (2008) 230–242. http://dx.doi.org/10.1007/s00223-008-9168-8
(PMID: 18787885).
[30] S. Marelli, F. Pace, Rabeprazole for the treatment of acid-related disorders, Expert
Rev. Gastroenterol. Hepatol. 6 (2012) 423–435. http://dx.doi.org/10.1586/egh.12.
18 (PMID: 22928894).
[31] D. Neri, C.T. Supuran, Interfering with pH regulation in tumours as a therapeutic
strategy, Nat. Rev. Drug Discov. 10 (2011) 767–777. http://dx.doi.org/10.1038/
nrd3554 (PMID: 21921921).
[32] T. Nishisho, K. Hata, M. Nakanishi, Y. Morita, G.H. Sun-Wada, Y. Wada, N. Yasui, T.
Yoneda, The a3 isoform vacuolar type H+-ATPase promotes distant metastasis in
the mouse B16 melanoma cells, Mol. Cancer Res. 9 (2011) 845–855. http://dx.doi.
org/10.1158/1541-7786.MCR-10-0449 (PMID: 21669964).
[33] H. Lincet, P. Icard, How do glycolytic enzymes favour cancer cell proliferation by
nonmetabolic functions? Oncogene 29 (Sep 2014)http://dx.doi.org/10.1038/onc.
2014.320 (PMID: 25263450).
[34] A.P. Halestrap, Monocarboxylic acid transport, Compr. Physiol. 3 (2013) 1611–1643.
http://dx.doi.org/10.1002/cphy.c130008 (PMID: 24265240).
[35] J.R. Doherty, J.L. Cleveland, Targeting lactate metabolism for cancer therapeutics, J.
Clin. Invest. 123 (2013) 3685–3692. http://dx.doi.org/10.1172/JCI69741 (PMID:
23999443).
[36] J. Doyen, C. Trastour, F. Ettore, I. Peyrottes, N. Toussant, J. Gal, K. Ilc, D. Roux, S.K.
Parks, J.M. Ferrero, J. Pouysségur, Expression of the hypoxia-inducible monocarbox-
ylate transporter MCT4 is increased in triple negative breast cancer and correlates
independently with clinical outcome, Biochem. Biophys. Res. Commun.
(2014)http://dx.doi.org/10.1016/j.bbrc.2014.07.050 (PMID: 25058459).
[37] L.H. Bergersen, Is lactate food for neurons? Comparison of monocarboxylate
transporter subtypes in brain and muscle, Neuroscience 145 (2007) 11–19. http://
dx.doi.org/10.1016/j.neuroscience.2006.11.062 (PMID:17218064).
[38] A. Suzuki, S.A. Stern, O. Bozdagi, G.W. Huntley, R.H. Walker, P.J. Magistretti, C.M.
Alberini, Astrocyte-neuron lactate transport is required for long-term memory for-
mation, Cell 144 (2011) (2011) 810–823. http://dx.doi.org/10.1016/j.cell.2011.02.
018 (PMID: 21376239).
[39] Q. Wang, M.E. Morris, The role of monocarboxylate transporter 2 and 4 in the
transport of gamma-hydroxybutyric acid in mammalian cells, Drug Metab. Dispos.
35 (2007) 1393–1399. http://dx.doi.org/10.1124/dmd.107.014852 (PMID:
17502341).
[40] D.B. Mach, S.D. Rogers, M.C. Sabino, N.M. Luger, M.J. Schwei, J.D. Pomonis, C.P.
Keyser, D.R. Clohisy, D.J. Adams, P. O'Leary, P.W. Mantyh, Origins of skeletal pain:
sensory and sympathetic innervation of the mouse femur, Neuroscience 113
(2002) 155–166. http://dx.doi.org/10.1016/S0306-4522(02)00165-3 (PMID:
12123694).
[41] R.R. Cooper, Nerves in cortical bone, Science 160 (1968) 327–328. http://dx.doi.org/
10.1126/science.160.3825.327 (PMID: 5641266).
[42] C.M. Serre, D. Farlay, P.D. Delmas, C. Chenu, Evidence for a dense and intimate
innervation of the bone tissue, including glutamate-containing ﬁbers, Bone 25
(1999) 623–629. http://dx.doi.org/10.1016/S8756-3282(99)00215-X (PMID:
10593406).
[43] K. Irie, F. Hara-Irie, H. Ozawa, T. Yajima, Calcitonin gene-related peptide (CGRP)-
containing nerve ﬁbers in bone tissue and their involvement in bone remodeling,
Microsc. Res. Tech. 58 (2002) 85–90. http://dx.doi.org/10.1002/jemt.10122 (PMID:
12203707).
[44] T. Fukuda, S. Takeda, R. Xu, H. Ochi, S. Sunamura, T. Sato, S. Shibata, Y. Yoshida, Z. Gu,
A. Kimura, C. Ma, C. Xu, W. Bando, K. Fujita, K. Shinomiya, T. Hirai, Y. Asou, M.
Enomoto, H. Okano, A. Okawa, H. Itoh, Sema3A regulates bone-mass accrual through
2684 T. Yoneda et al. / Biochimica et Biophysica Acta 1848 (2015) 2677–2684sensory innervations, Nature 497 (2013) 490–493. http://dx.doi.org/10.1038/
nature12115 (PMID: 23644455).
[45] S. Benemei, P. Nicoletti, J.G. Capone, P. Geppetti, CGRP receptors in the control of
pain and inﬂammation, Curr. Opin. Pharmacol. 9 (2009) 9–14. http://dx.doi.org/
10.1016/j.coph.2008.12.007 (PMID: 19157980).
[46] A.M. Salmon, M.I. Damaj, L.M. Marubio, M.P. Epping-Jordan, E. Merlo-Pich, J.P.
Changeux, Altered neuroadaptation in opiate dependence and neurogenic
inﬂammatory nociception in alpha CGRP-deﬁcient mice, Nat. Neurosci. 4 (2001)
357–358. http://dx.doi.org/10.1038/86001 (PMID: 11276224).
[47] P. Mantyh, Bone cancer pain: causes, consequences, and therapeutic opportunities,
Pain 154 (Suppl. 1) (2013) S54–S62. http://dx.doi.org/10.1016/j.pain.2013.07.044
(PMID: 23916671).
[48] A.I. Basbaum, D.M. Bautista, G. Scherrer, D. Julius, Cellular and molecular
mechanisms of pain, Cell 139 (2009) 267–284. http://dx.doi.org/10.1016/j.cell.
2009.09.028 (PMID: 19837031).
[49] W.G. Mantyh, J.M. Jimenez-Andrade, J.I. Stake, A.P. Bloom, M.J. Kaczmarska, R.N.
Taylor, K.T. Freeman, J.R. Ghilardi, M.A. Kuskowski, P.W. Mantyh, Blockade of
nerve sprouting and neuroma formation markedly attenuates the development of
late stage cancer pain, Neuroscience 171 (2010) 588–598. http://dx.doi.org/10.
1016/j.neuroscience.2010.08.056 (PMID: 20851743).
[50] M.J. Caterina, A. Lefﬂer, A.B. Malmberg, W.J. Martin, J. Trafton, K.R. Petersen-Zeitz, M.
Koltzenburg, A.I. Basbaum, D. Julius, Impaired nociception and pain sensation in
mice lacking the capsaicin receptor, Science 288 (2000) 306–313. http://dx.doi.
org/10.1126/science.288.5464.306 (PMID: 10764638).
[51] K.W. Ho, N.J. Ward, D.J. Calkins, TRPV1: a stress response protein in the central
nervous system, Am. J. Neurodegener. Dis. 1 (2012) 1–14 (PMID: 22737633).
[52] L. Lieben, G. Carmeliet, The involvement of TRP channels in bone homeostasis, Front.
Endocrinol. (Lausanne) 3 (2012) 99. http://dx.doi.org/10.3389/fendo.2012.00099
(PMID: 22934090).
[53] M. Nakanishi, K. Hata, T. Nagayama, T. Sakurai, T. Nishisho, H. Wakabayashi, T.
Hiraga, S. Ebisu, T. Yoneda, Acid activation of Trpv1 leads to an up-regulation of
calcitonin gene-related peptide expression in dorsal root ganglion neurons via the
CaMK-CREB cascade: a potential mechanism of inﬂammatory pain, Mol. Biol. Cell
21 (2010) 2568–2577. http://dx.doi.org/10.1091/mbc.E10-01-0049 (PMID:
20534813).
[54] P.W. Mantyh, The neurobiology of skeletal pain, Eur. J. Neurosci (2014). http://dx.
doi.org/10.1111/ejn.12462 (PMID: 24494689).
[55] T. Yoneda, K. Hata, M. Nakanishi, M. Nagae, T. Nagayama, H. Wakabayashi, T.
Nishisho, T. Sakurai, T. Hiraga, Involvement of acidic microenvironment in the
pathophysiology of cancer-associated bone pain, Bone. 48 (2011) 100–105. http://
dx.doi.org/10.1016/j.bone.2010.07.009 (PMID: 20637323).
[56] Y. Niiyama, T. Kawamata, J. Yamamoto, K. Omote, A. Namiki, Bone cancer increases
transient receptor potential vanilloid subfamily 1 expression within distinct
subpopulations of dorsal root ganglion neurons, Neuroscience 148 (2007)
560–572. http://dx.doi.org/10.1016/j.neuroscience.2007.05.049 (PMID: 17656027).
[57] J.R. Ghilardi, H. Röhrich, T.H. Lindsay, M.A. Sevcik, M.J. Schwei, K. Kubota, K.G.
Halvorson, J. Poblete, S.R. Chaplan, A.E. Dubin, N.I. Carruthers, D. Swanson, M.
Kuskowski, C.M. Flores, D. Julius, P.W. Mantyh, Selective blockade of the capsaicin
receptor TRPV1 attenuates bone cancer pain, J. Neurosci. 25 (2005) 3126–3131.
http://dx.doi.org/10.1523/JNEUROSCI.3815-04.2005 (PMID: 15788769).
[58] Y. Niiyama, T. Kawamata, J. Yamamoto, S. Furuse, A. Namiki, SB366791, a TRPV1
antagonist, potentiates analgesic effects of systemic morphine in a murine model
of bone cancer pain, Br. J. Anaesth. 102 (2009) 251–258. http://dx.doi.org/10.
1093/bja/aen347 (PMID: 19038965).
[59] J.D. Brederson, P.R. Kym, A. Szallasi, Targeting TRP channels for pain relief, Eur. J.
Pharmacol. 716 (2013) 61–76. http://dx.doi.org/10.1016/j.ejphar.2013.03.003
(PMID: 23500195).
[60] Q. Xu, X.M. Zhang, K.Z. Duan, X.Y. Gu, M. Han, B.L. Liu, Z.Q. Zhao, Y.Q. Zhang, Periph-
eral TGF-β1 signaling is a critical event in bone cancer-induced hyperalgesia in
rodents, J. Neurosci. 33 (2013) 19099–19111. http://dx.doi.org/10.1523/
JNEUROSCI.4852-12.2013 (PMID: 24305807).
[61] Y. Li, J. Cai, Y. Han, X. Xiao, X.L. Meng, L. Su, F.Y. Liu, G.G. Xing, Y. Wan, Enhanced
function of TRPV1 via up-regulation by insulin-like growth factor-1 in a rat model
of bone cancer pain, Eur. J. Pain 18 (2014) 774–784. http://dx.doi.org/10.1002/j.
1532-2149.2013.00420.x (PMID: 24827675).
[62] A.D. de la Rosa, P. Zhang, D. Shao, F. White, C.M. Canessa, Functional implications of
the localization and activity of acid-sensitive channels in rat peripheral nervoussystem, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2326–2331. http://dx.doi.org/10.
1073/pnas.042688199 (PMID: 11842212).
[63] W.L. Wu, C.F. Cheng, W.H. Sun, C.W. Wong, C.C. Chen, Targeting ASIC3 for pain,
anxiety, and insulin resistance, Pharmacol. Ther. 134 (2012) 127–138. http://dx.
doi.org/10.1016/j.pharmthera.2011.12.009 (PMID: 22233754).
[64] M. Ikeuchi, S.J. Kolker, K.A. Sluka, Acid-sensing ion channel 3 expression in mouse
knee joint afferents and effects of carrageenan-induced arthritis, J. Pain 10 (2009)
336–342. http://dx.doi.org/10.1016/j.jpain.2008.10.010 (PMID: 19185546).
[65] T.H. Olson, M.S. Riede, L. Vulchanova, X.R. Ortiz-Gonzalez, R. Elde, An acid sensing
ion channel (ASIC) localizes to small primary afferent neurons in rats, NeuroReport
9 (1998) 1109–1113 (PMID: 9601677).
[66] H. Jahr, M. van Driel, G.J. van Osch, H. Weinans, J.P. van Leeuwen, Identiﬁcation of
acid-sensing ion channels in bone, Biochem. Biophys. Res. Commun. 337 (2005)
349–354. http://dx.doi.org/10.1016/j.bbrc.2005.09.054 (PMID: 16185661).
[67] Y. Yu, Z. Chen, W.G. Li, H. Cao, E.G. Feng, F. Yu, H. Liu, H. Jiang, T.L. Xu, A nonproton
ligand sensor in the acid-sensing ion channel, Neuron 68 (2010) 61–72. http://dx.
doi.org/10.1016/j.neuron.2010.09.001 (PMID: 20920791).
[68] J.A.Wemmie, R.J. Taugher, C.J. Kreple, Acid-sensing ion channels in pain and disease,
Nat. Rev. Neurosci. 14 (2013) 461–471. http://dx.doi.org/10.1038/nrn3529 (PMID:
23783197).
[69] F. Qiu, X. Wei, S. Zhang, W. Yuan, W. Mi, Increased expression of acid-sensing ion
channel 3 within dorsal root ganglia in a rat model of bone cancer pain, Neuroreport
25 (2014) 887–893. http://dx.doi.org/10.1097/WNR.0000000000000182 (PMID:
25006846).
[70] P. Feldman, M.R. Due, M.S. Ripsch, R. Khanna, F.A. White, The persistent release of
HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain,
J. Neuroinﬂammation 9 (2012) 180. http://dx.doi.org/10.1186/1742-2094-9-180
(PMID: 22824385).
[71] S. Diochot, A. Baron, L.D. Rash, E. Deval, P. Escoubas, S. Scarzello, M. Salinas, M.
Lazdunski, A new sea anemone peptide, APETx2, inhibits ASIC3, a major acid-
sensitive channel in sensory neurons, EMBO J. 23 (2004) 1516–1525. http://dx.
doi.org/10.1038/sj.emboj.7600177 (PMID: 15044953).
[72] J. Karczewski, R.H. Spencer, V.M. Garsky, A. Liang, M.D. Leitl, M.J. Cato, S.P. Cook, S.
Kane, M.O. Urban, Reversal of acid-induced and inﬂammatory pain by the selective
ASIC3 inhibitor, APETx2, Br. J. Pharmacol. 161 (2010) 950–960. http://dx.doi.org/10.
1111/j.1476-5381.2010.00918.x (PMID: 20860671).
[73] M. Izumi, M. Ikeuchi, Q. Ji, T. Tani, Local ASIC3 modulates pain and disease
progression in a rat model of osteoarthritis, J. Biomed. Sci. 19 (2012) 77. http://dx.
doi.org/10.1186/1423-0127-19-77 (PMID: 22909215).
[74] L.S. Premkumar, M. Abooj, TRP channels and analgesia, Life Sci. 92 (2013) 415–424.
http://dx.doi.org/10.1016/j.lfs.2012.08.010 (PMID: 22910182).
[75] O. Egbuniwe, S. Grover, A.K. Duggal, A. Mavroudis, M. Yazdi, T. Renton, L. Di Silvio,
A.D. Grant, TRPA1 and TRPV4 activation in human odontoblasts stimulates ATP
release, J. Dent. Res. 93 (2014) 911–917. http://dx.doi.org/10.1177/
0022034514544507 (PMID: 25062738).
[76] E. Abed, D. Labelle, C. Martineau, A. Loghin, R. Moreau, Expression of transient
receptor potential (TRP) channels in human and murine osteoblast-like cells, Mol.
Membr. Biol. 26 (2009) 146–158. http://dx.doi.org/10.1080/09687680802612721
(PMID: 19115145).
[77] J. Chen, Y. Luan, R. Yu, Z. Zhang, J. Zhang, W. Wang, et al., Transient receptor
potential (TRP) channels, promising potential diagnostic and therapeutic tools for
cancer, Biosci. Trends 8 (2014) 1–10. http://dx.doi.org/10.5582/bst.8.1 (PMID:
24647107).
[78] E. Schipani, C. Maes, G. Carmeliet, G.L. Semenza, Regulation of osteogenesis–angio-
genesis coupling by HIFs and VEGF, J. Bone Miner. Res. 24 (2009) 1347–1353.
http://dx.doi.org/10.1359/jbmr.090602 (PMID: 19558314).
[79] R.J. Gillies, D. Verduzco, R.A. Gatenby, Evolutionary dynamics of carcinogenesis and
why targeted therapy does not work, Nat. Rev. Cancer 12 (2012) 487–493. http://
dx.doi.org/10.1038/nrc3298 (PMID: 22695393).
[80] S. Peppicelli, F. Bianchini, L. Calorini, Extracellular acidity, a “reappreciated” trait of
tumor environment driving malignancy: perspectives in diagnosis and therapy,
Cancer Metastasis Rev. 33 (2014) 823–832. http://dx.doi.org/10.1007/s10555-014-
9506-4 (PMID: 24984804).
[81] S. Paget, The distribution of secondary growths in cancer of the breast, Lancet 8
(1889) 98–101 (PMID: 2673568).
